about
Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor HypoxiaThe histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibitionSurvival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas.Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluationHistone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cellsA therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.Two mutations impair the stability and function of ubiquitin-activating enzyme (E1)Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy.Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formationHIF-1 at the crossroads of hypoxia, inflammation, and cancer.AMPK-HDAC5 pathway facilitates nuclear accumulation of HIF-1α and functional activation of HIF-1 by deacetylating Hsp70 in the cytosolAcetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastomaGlutamine depletion and glucose depletion trigger growth inhibition via distinctive gene expression reprogramming.Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells.Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers.The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective.Panobinostat for the treatment of multiple myeloma.The epigenetic effects of butyrate: potential therapeutic implications for clinical practice.Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia.Effect of Niacin on Inflammation and Angiogenesis in a Murine Model of Ulcerative Colitis.Release the ink4a/arf growth suppression by "u" and "me"?Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
P2860
Q26783014-5C24B397-567D-4975-A2FD-6C425741FD09Q28542639-FF5D3018-6F41-47AA-9C9A-BEEDE974D802Q33587519-472AF3E7-D533-448B-B9E0-2E11A00C980DQ33705588-3694A12C-44AF-428C-A2B8-F261FB6D54F9Q33829390-4C43D22E-813F-4D2C-8D26-B1FF0B3A0F35Q34102029-C48CEC03-288C-48FB-8CE6-8EED94914C0AQ34382527-2041C50C-8C44-45AC-A421-79BF354C280DQ34619590-A2F48A41-50B8-4ECB-A237-E2656A38F1DEQ35163974-C57BEDE1-E76A-4085-9198-292F835D5F43Q35250252-DC64CCD0-B06C-4861-B65E-250BBDDC7586Q35554901-FBE253E1-FDC3-4832-A417-000FA350E49BQ35841917-8D88C59E-0E51-46E5-995F-4121375CD57CQ35920463-4B5A123B-CFC0-4DE5-A0A5-BCE493B3B49CQ36070195-63B46363-E6F6-44A4-B2A8-BE328C9865B0Q36186609-9F3A67D5-3A3C-4987-A7A3-2402160CE1EDQ36290436-220BF3AC-87C9-464A-B79D-DF16FAD8E198Q36338778-D94D92EF-57FB-41DA-8D9C-58ACD46D4CEBQ36470446-CD65F5CC-0859-42F7-ABB6-7047A4BAF3C8Q37162642-2AB96F54-3A5F-427C-A286-494E7CF96857Q37884379-B4DEFFB8-3128-4066-BF4A-A65DDC241A25Q37943792-F5F076B2-B1F8-4A84-85F3-D538B55276F6Q37992104-E05F6F55-E8B4-4308-9C1F-3DF71478CC12Q37993265-6070EB04-A407-4048-915A-97D09E496D05Q38031633-904864E9-338E-4A70-806F-610E159B8326Q39968880-29715BFE-BB75-4C8C-B304-16137DD2ECCBQ41221924-F187C40A-001C-4BA7-876C-B23CEB4D2AC2Q43006052-739C03EA-6A2B-418E-AE97-CD7CE05FA1ECQ51374040-969B7E9B-ACD4-4633-ABE3-3B327336945CQ55485574-7E376FCD-BC27-4DC2-9CB1-A8ABA52BDBFC
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Effects of histone deacetylase inhibitors on HIF-1
@ast
Effects of histone deacetylase inhibitors on HIF-1
@en
Effects of histone deacetylase inhibitors on HIF-1
@nl
type
label
Effects of histone deacetylase inhibitors on HIF-1
@ast
Effects of histone deacetylase inhibitors on HIF-1
@en
Effects of histone deacetylase inhibitors on HIF-1
@nl
prefLabel
Effects of histone deacetylase inhibitors on HIF-1
@ast
Effects of histone deacetylase inhibitors on HIF-1
@en
Effects of histone deacetylase inhibitors on HIF-1
@nl
P2093
P2860
P3181
P356
P1433
P1476
Effects of histone deacetylase inhibitors on HIF-1
@en
P2093
Dongming Liang
Nianli Sang
Xianguo Kong
P2860
P304
P3181
P356
10.4161/CC.5.21.3409
P407
P577
2006-11-01T00:00:00Z